| 1 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7073).
|
| 2 |
Exemestane FDA Label
|
| 3 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
| 4 |
ClinicalTrials.gov (NCT00201773) Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
|
| 5 |
ClinicalTrials.gov (NCT00525096) Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
|
| 6 |
ClinicalTrials.gov (NCT00863655) Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
|
| 7 |
ClinicalTrials.gov (NCT01626222) 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
|
| 8 |
ClinicalTrials.gov (NCT02077933) Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
|
| 9 |
ClinicalTrials.gov (NCT02732119) Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
|
| 10 |
ClinicalTrials.gov (NCT01153672) Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
|
| 11 |
ClinicalTrials.gov (NCT00719966) Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
|
| 12 |
ClinicalTrials.gov (NCT00793546) Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
|
| 13 |
ClinicalTrials.gov (NCT01597193) Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
|
| 14 |
ClinicalTrials.gov (NCT01431053) Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
|
| 15 |
ClinicalTrials.gov (NCT01004081) Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
|
| 16 |
ClinicalTrials.gov (NCT01605396) A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064). U.S. National Institutes of Health.
|
| 17 |
ClinicalTrials.gov (NCT00676663) Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
|
| 18 |
ClinicalTrials.gov (NCT00432172) Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
|
| 19 |
ClinicalTrials.gov (NCT01664754) Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
|
| 20 |
ClinicalTrials.gov (NCT01857193) Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
|
| 21 |
ClinicalTrials.gov (NCT01870505) BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
|
| 22 |
ClinicalTrials.gov (NCT00201864) Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
|
| 23 |
ClinicalTrials.gov (NCT01005641) ELBA: Exemestane and Lapatinib in Advanced Breast Cancer
|
| 24 |
ClinicalTrials.gov (NCT02057133) A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
|
| 25 |
ClinicalTrials.gov (NCT01594216) Ruxolitinib in Estrogen Receptor Positive Breast Cancer
|
| 26 |
ClinicalTrials.gov (NCT01963481) Exemestane and Cyclophosphamide for Metastatic Breast Cancer
|
| 27 |
ClinicalTrials.gov (NCT02648477) Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
|
| 28 |
ClinicalTrials.gov (NCT00573755) Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
|
| 29 |
ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
|
| 30 |
ClinicalTrials.gov (NCT02995772) Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
|
| 31 |
ClinicalTrials.gov (NCT00893061) Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
|
| 32 |
ClinicalTrials.gov (NCT06016738) OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
|
|
|
|
|
|
|
